Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies.
Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice® fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice® fully human antibody platform, highlighting our ability to empower partners in driving innovative drug discovery. We look forward to seeing these promising molecules progress rapidly into the clinic and ultimately bring transformative treatment options to patients worldwide.”
Under the terms of the agreement, Biocytogen will receive an upfront payment from BeOne Medicines. In addition, Biocytogen is eligible to receive development and regulatory milestone payments, commercial milestone payments, and tiered royaltiesbased on future net sales of licensed products.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250709188805/en/
Contacts
Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Announces Early Access Waitlist for Pioneering $MBG Token10.7.2025 13:30:00 EEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has opened the waitlist for its highly anticipated $MBG Token, ushering in a new era that bridges traditional finance and blockchain technology. The presale will take place in July 2025, with priority access now available at: token.multibankgroup.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710986556/en/ MultiBank Group Announces Early Access Waitlist for Pioneering $MBG Token Unlike typical speculative offerings, the $MBG Token stands apart as a next-generation utility token, supported by tangible assets worth $29 billion and daily trading volumes exceeding $35 billion (as of April 2025). It is designed to introduce genuine revenue streams, advanced infrastructure, and market-level trust to the digital asset space. The $MBG Token is built on MultiBank Group’s robust ecosystem, which spans four core domains: MultiBank Tra
European Commission Approves TEVIMBRA ® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma10.7.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper part of the throat located behind the nose.1 “The approval of TEVIMBRA combined with chemotherapy in Europe marks an important advancement for people with recurrent or metastatic nasopharyngeal carcinoma—a rare and challenging disease,” said Prof. Lisa Licitra, Chief of the Head and Neck Cancer Medical Oncology Department at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. “Thanks to the compelling results from the RATIONALE-309 study, we now have a powerful new treatment that not only delays disease
Alpaca Enters UK and EU Market through WealthKernel Acquisition10.7.2025 11:30:00 EEST | Press release
Alpaca, a self-clearing broker-dealer and brokerage infrastructure API, today announced its intended acquisition of WealthKernel, a wealthtech firm specializing in digital investment infrastructure and tax-advantaged products. This strategic acquisition will bring WealthKernel’s UK and EU licensed brokerage infrastructure to Alpaca, supporting their rapid global expansion to achieve its mission of opening financial services to everyone on the planet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710149866/en/ Alpaca, a self-clearing broker-dealer and brokerage infrastructure API, today announced its intended acquisition of WealthKernel, a wealthtech firm specializing in digital investment infrastructure and tax-advantaged products. "The acquisition of WealthKernel is a major step for Alpaca in becoming a truly global brokerage infrastructure. WealthKernel has gained a highly regarded reputation in the UK and EU through w
IQM Announces Major Upgrade to Resonance Quantum Cloud Platform With New Software Development Kit10.7.2025 11:09:00 EEST | Press release
IQM Quantum Computers, a global leader in building quantum computers, today announced a major upgrade to its quantum computing cloud platform, IQM Resonance, to accelerate the development of quantum algorithms with new software tools and provide end-users with a powerful new quantum system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710268218/en/ IQM Resonance The upgrade features Qrisp – a project started at Fraunhofer FOKUS – as the new default software development kit (SDK). Qrisp offers a highly powerful but easy to learn higher level programming interface for quantum developers and researchers. The Qrisp framework is and stays open source. With the new software development kit becoming the default, IQM continues to support other popular quantum programming frameworks such as Qiskit, Cirq, Cuda Quantum, and TKET ensuring flexibility for all users. IQM’s comprehensive and open approach to quantum development builds
Brightcove Unveils Its New Vision for the Future of Video Engagement, Powered by Proprietary AI and Customer Insight10.7.2025 11:00:00 EEST | Press release
Brightcove, the intelligent video engagement company, has today unveiled a bold new chapter in its evolution, signaling a renewed commitment to innovation, customer-centricity and meaningful digital experiences. Backed by new owner Bending Spoons, and incorporating its powerful proprietary AI technology, Brightcove is reimagining its platform to meet the growing demands of both Media and Enterprise customers. This marks a strategic evolution in how Brightcove approaches product development, balancing cutting-edge innovation with a relentless focus on quality of experience. The company is investing in areas that matter most to its customers, including new AI-powered features developed in-house, enhanced monetization tools, and a more intuitive user experience. Brightcove’s new direction is the result of extensive collaboration with more than 50 customers across industries, geographies, and use cases. These conversations have shaped a product strategy that is designed to meet the evolvin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom